View this interactive prIME Infographic to learn more about PARP inhibitors in breast cancer, including mechanism of action, biomarkers, recent clinical trial results, and safety.
Nov 21, 2017
Nov 21, 2018
Pierfranco Conte, MDIstituto Oncologico Veneto
University of Padua
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
Andrew Tutt, MD, PhDInstitute of Cancer Research
London, United Kingdom
- Rationale for PARP inhibition in breast cancer
- Mechanism of action
- PARP inhibitors in metastatic breast cancer
- PARP inhibitors in early breast cancer
- prIME Points™
This educational activity is designed for surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with breast cancer.
After successful completion of this educational activity, participants should be able to:
- Describe the impact of BRCA1/2 testing on clinical outcomes for patients with breast cancer
- Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
- Select optimal treatment options, based on current treatment guidelines and emerging clinical trial data, for patients with triple-negative and BRCA-mutated breast cancer
This educational activity is supported by a grant from AstraZeneca.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and Independent Medical Education (IME) performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.